Bayer profits up 11.5 percent on new drugs

German chemical and pharmaceutical company Bayer AG said Thursday that its net profit rose 11.5 percent in the first quarter as new drugs, led by blood thinner Xarelto, boosted sales.

The company also saw stronger demand in emerging markets—which helped overcome weaker business in Europe, which is in a recession.

Overall, Bayer said its net income rose to 1.16 billion euros ($1.51 billion) from 1.04 billion in the same quarter a year earlier and that revenue rose 2.1 percent to 10.2 billion euros.

The standout performance was Xarelto, which more than tripled sales to 155 million euros. The drug's uses include preventing potentially life threatening blood clots that can form in people who have had hip or .

The company said it also had strong results from cancer drug Stivarga and from Eylea, which is used to treat the eye disease macular degeneration.

Elsewhere, Bayer said health care sales rose 7.6 percent in Asia and 4.5 percent in North America, outpacing Europe at 1.9 percent.

The company also saw continuing strong demand for its farm products such as seeds and crop protection chemicals, and that despite a late start to the growing season in the . That division raised its sales by 5.9 percent thanks to persistently high price levels for agricultural commodities.

The company stood by its forecast for a high-single digit percentage increase in profits and an increase in sales of between 4 percent and 5 percent.

0 shares

Related Stories

SAP says profits up in first quarter

date Apr 13, 2012

German software giant SAP said on Friday it was sticking to its full-year targets for 2012 after profits rose in the first three months.

Merck Q4 net profit more than doubles

date Mar 07, 2013

Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.

Amadeus quarterly profit soars 30 percent

date Aug 03, 2012

Spain's Amadeus, the world's biggest processor of travel bookings, on Friday announced second-quarter net profits of 164.6 million euros ($200.9 million), up 30.3 percent on the same period last year.

Recommended for you

FDA reviewing safety of Essure birth control implant

date Jun 25, 2015

Federal health regulators are reviewing the safety of an implantable contraception device after receiving reports of unusual side effects from patients, including fatigue, depression and weight gain.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.